Nurses Revision

acromegaly and gigantism

Acromegaly & Gigantism (Hyperpituitarism)

Text size
On this page

Overview of Acromegaly and Gigantism (Hyperpituitarism)

Hyperpituitarism is the excessive secretion of one or more hormones by the pituitary gland. Acromegaly and gigantism are endocrine disorders caused by chronic hypersecretion of growth hormone (GH)—also known as somatotropin—from the anterior pituitary gland, leading to elevated circulating insulin-like growth factor 1 (IGF-1) and progressive overgrowth of skeletal, cartilage, connective, and visceral tissues.

Although both conditions share the same underlying hormonal excess, the clinical presentation depends on whether the epiphyseal growth plates of the long bones have fused:

  • Gigantism: Occurs in children or adolescents before fusion of the epiphyses and diaphyses (growth plate closure). Prolonged GH excess causes accelerated linear bone growth, resulting in abnormally tall stature (often exceeding 7–8 feet if untreated) with largely proportional body features.
  • Acromegaly: Occurs in adults after epiphyseal growth plates have closed. Because linear height can no longer increase, GH excess stimulates periosteal (appositional) bone thickening and soft-tissue overgrowth, producing characteristic enlargement of the acral parts (hands, feet, and craniofacial bones).

Key Point: Timing of GH Excess

Before growth plate fusion → Gigantism (excessive vertical height). After growth plate fusion → Acromegaly (thickening of bones and soft tissues of the hands, feet, and face).

Etiology and Risk Factors

  • GH-Secreting Pituitary Adenoma: Accounts for over 95% of cases. It is almost always a benign somatotroph adenoma of the anterior pituitary (most commonly a macroadenoma >10 mm at diagnosis). Some adenomas co-secrete prolactin (mammosomatotroph adenomas).
  • Local Mass Compression Effects: As the pituitary tumor enlarges within the sella turcica, it can compress surrounding structures and cause:
    • Hypopituitarism: Reduced secretion of other anterior pituitary hormones (TSH, ACTH, FSH, LH) or posterior pituitary antidiuretic hormone (ADH).
    • Optic Chiasm Compression: Visual field defects—classically bitemporal hemianopsia (loss of outer/peripheral vision)—and persistent headaches.
  • Rare Non-Pituitary Causes (<5%): Excessive hypothalamic growth hormone-releasing hormone (GHRH) secretion, ectopic GHRH or GH production from neuroendocrine tumors (e.g., bronchial carcinoid or pancreatic islet cell tumors), or familial syndromes such as Multiple Endocrine Neoplasia type 1 (MEN1) and Carney complex.

Pathophysiology

Normally, the hypothalamus regulates anterior pituitary GH release through a balance of stimulation by GHRH and inhibition by somatostatin, with GH secreted in brief pulses. In hyperpituitarism, an autonomous pituitary adenoma secretes excessive GH continuously regardless of normal negative feedback.

  1. Excess GH Secretion: Elevated circulating GH acts directly on metabolic tissues and travels to the liver and peripheral tissues.
  2. Increased IGF-1 Production: GH stimulates hepatic synthesis and release of IGF-1, which mediates most of the somatic growth-promoting actions of GH.
  3. Tissue and Organ Overgrowth: Sustained elevation of GH and IGF-1 drives excessive proliferation of bone, articular cartilage, periosteum, connective tissue, skin appendages, and internal organs (visceromegaly).
  4. Metabolic Antagonism to Insulin: Excess GH exerts strong anti-insulin (diabetogenic) effects by promoting lipolysis, increasing hepatic gluconeogenesis, and reducing peripheral glucose uptake, leading to impaired glucose tolerance and secondary diabetes mellitus.
  5. Cardiovascular and Renal Sodium Retention: GH and IGF-1 promote myocardial hypertrophy, vascular remodeling, and renal sodium/water reabsorption, predisposing the patient to hypertension, cardiomegaly, and heart failure.

Clinical Manifestations

Clinical features develop insidiously over several years, often delaying diagnosis until irreversible skeletal changes or mass-effect symptoms appear.

Diagram showing clinical manifestations of acromegaly and gigantism including coarse facial features, prognathism, enlarged hands and feet, and excessive height
Clinical manifestations of acromegaly and gigantism

Systemic Signs and Symptoms

  • Acral and Musculoskeletal Changes:
    • Enlarged Hands and Feet: Thickened, spade-like fingers and broadened feet, often noticed through increasing ring, glove, and shoe sizes.
    • Arthropathy and Spinal Deformity: Cartilage hypertrophy followed by joint degeneration causes joint pain, stiffness, limited range of motion, and thoracic kyphosis.
    • Abnormal Linear Growth (Gigantism only): Rapidly increasing height above the 97th percentile in children and adolescents.
  • Craniofacial and Oral Changes:
    • Coarse Facial Features: Prominent forehead (frontal bossing), pronounced supraorbital ridges, enlarged nose, and thickened lips.
    • Prognathism and Dental Changes: Protrusion of the lower jaw, widened spaces between teeth, and malocclusion.
    • Macroglossia and Voice Changes: Enlarged tongue causing dysarthria (slurred speech) and dysphagia; laryngeal and sinus hypertrophy causing a deep, hollow voice.
  • Integumentary Changes: Thickened, oily skin, hyperhidrosis (excessive sweating with characteristic odor), skin tags (acrochordons), acanthosis nigricans (marker of insulin resistance), and increased body hair.
  • Cardiopulmonary and Airway Effects: Obstructive sleep apnea (OSA) and loud snoring from pharyngeal soft-tissue thickening and macroglossia; hypertension, cardiomegaly, arrhythmias, and congestive heart failure.
  • Neurological and Visual Effects: Chronic headaches, bitemporal hemianopsia or blurred vision from optic chiasm compression, and carpal tunnel syndrome (paresthesia, numbness, and weakness of the hands due to median nerve compression by hypertrophied soft tissue).
  • Visceral and Endocrine/Metabolic Effects: Enlargement of internal organs (heart, liver, spleen, kidneys, and thyroid goiter); polyuria and polydipsia from secondary diabetes mellitus; menstrual irregularities/amenorrhea and galactorrhea in females; and erectile dysfunction (impotence) or reduced libido in males.

Comparison Between Acromegaly and Gigantism

Clinical FeatureAcromegalyGigantism
OnsetAdulthood (after epiphyseal growth plate closure)Childhood or adolescence (before epiphyseal growth plate closure)
HeightNormal adult height (growth plates already fused)Abnormally increased linear height (often >7 feet if untreated)
Facial FeaturesEnlarged jaw (prognathism), nose, and brow; coarse facial featuresInitially proportional, gradually developing coarse features with age
Hand and Foot SizeBroad, thickened hands and feet with doughy soft tissueLarge hands and feet proportional to tall body stature
Joint PainCommon due to articular cartilage hypertrophy and osteoarthritisMay occur, especially as the individual grows into adulthood
Skin ChangesThick, oily skin; excessive sweating (hyperhidrosis); skin tagsThickened skin and increased sweating may develop
Organ Enlargement (Visceromegaly)Common (cardiomegaly, hepatomegaly, splenomegaly, goiter)Possible due to generalized visceral overgrowth
Cardiovascular ComplicationsHypertension, left ventricular hypertrophy, cardiomyopathyMay develop hypertension and cardiomyopathy over time
Bone and Soft Tissue OvergrowthPeriosteal bone thickening, particularly in skull, jaw, hands, and feetGeneralized linear and soft-tissue overgrowth throughout the skeleton
Visual DisturbancesPossible (bitemporal hemianopsia) due to optic chiasm compressionPossible if macroadenoma compresses the optic chiasm
Other SymptomsHeadaches, fatigue, obstructive sleep apnea, carpal tunnel syndrome, diabetesHeadaches, fatigue, delayed puberty/hypogonadism if pituitary compressed

Advertisements

Diagnostic Evaluation

Diagnosis combines clinical recognition of gradual physical changes with biochemical confirmation of non-suppressible GH/IGF-1 excess and pituitary neuroimaging.

Clinical History and Physical Examination

  • Focused History: Review old photographs for progressive facial changes; inquire about increased shoe, ring, glove, or hat sizes; ask about headaches, peripheral vision loss, joint stiffness, loud snoring/daytime sleepiness, hyperhidrosis, menstrual irregularities, galactorrhea, or erectile dysfunction.
  • Physical Examination: Assess for acral enlargement, prognathism, dental spacing, macroglossia, coarse oily skin, goiter, hepatosplenomegaly, elevated blood pressure, confrontation visual field deficits, and positive Tinel or Phalen signs for carpal tunnel syndrome.

Biochemical, Imaging, and Supportive Investigations

  • Biochemical Tests:
    • Serum IGF-1: The most sensitive and reliable initial screening test. Because IGF-1 levels remain relatively stable throughout the day, an elevated age- and sex-adjusted IGF-1 level strongly indicates GH excess.
    • Oral Glucose Tolerance Test (OGTT) with GH Measurement: The gold-standard confirmatory test. Normally, administering 75 g of oral glucose suppresses serum GH below 1 μg/L (or <0.4 μg/L on ultrasensitive assays). Failure of GH to suppress confirms acromegaly or gigantism.
    • Random Serum GH: Less reliable on its own because GH is secreted in pulses and fluctuates widely with sleep, stress, fasting, and exercise.
  • Imaging Studies:
    • Pituitary MRI (with contrast): The gold-standard imaging study to identify a pituitary adenoma, determine its size (micro- vs. macroadenoma), and evaluate invasion into the cavernous sinus or optic chiasm.
    • CT Scan of the Sella: Alternative when MRI is unavailable or contraindicated, though MRI provides superior soft-tissue resolution.
  • Additional Endocrine and Complication Screening:
    • Anterior Pituitary Hormone Panel: Serum prolactin (frequently co-elevated), TSH and free T4, morning cortisol/ACTH, FSH, LH, and estradiol or testosterone to detect tumor-induced hypopituitarism.
    • Visual Field Testing (Perimetry): Formal ophthalmologic assessment to quantify optic chiasm compression (bitemporal hemianopsia).
    • Cardiovascular and Metabolic Evaluation: Fasting blood glucose and HbA1c, lipid profile, electrocardiogram (ECG), and echocardiogram to detect hypertension, left ventricular hypertrophy, and cardiomyopathy.
    • Sleep Study and Colonoscopy: Polysomnography for suspected obstructive sleep apnea; screening colonoscopy because chronic IGF-1 excess increases the risk of colonic polyps and colorectal malignancy.

Clinical Rationale: Why IGF-1 Is Preferred Over Random GH for Screening

Growth hormone has a short half-life (~20 minutes) and is released in episodic bursts, so a single random GH value may appear falsely normal or falsely elevated. IGF-1 has a longer half-life and reflects integrated 24-hour GH secretion, making it a stable and dependable screening marker.

Advertisements

Medical, Surgical, and Radiation Management

The goals of treatment are to normalize GH and IGF-1 levels, excise or shrink the pituitary tumor, relieve mass compression (especially on the optic chiasm), preserve remaining pituitary function, and manage systemic comorbidities.

Surgical Management (First-Line)

Transsphenoidal resection (hypophysectomy) is the primary treatment of choice for most patients with GH-secreting pituitary adenomas. The surgeon accesses and removes the tumor through the nasal cavity and sphenoid sinus without a craniotomy.

Pre-operative and Post-operative Transsphenoidal Nursing Care

  • Pre-operative Care: Establish baseline neurological status, visual acuity, and visual fields; educate the patient on post-operative precautions (do not blow the nose, cough forcefully, sneeze with the mouth closed, bend over, or strain at stool, as these raise intracranial pressure and risk a cerebrospinal fluid leak).
  • Post-operative Monitoring and Interventions:
    • Positioning and Airway: Elevate the head of the bed 30° to reduce intracranial pressure and facial edema; monitor airway patency closely in patients with macroglossia or sleep apnea.
    • CSF Leak Assessment: Inspect the nasal drip pad ("mustache dressing") frequently for clear, watery drainage. Check suspicious fluid for a yellow halo (ring) sign on gauze or positive glucose testing, and report suspected CSF rhinorrhea immediately.
    • Fluid and Electrolyte Surveillance: Measure strict hourly/daily intake and output, daily weights, urine specific gravity, and serum sodium to detect transient or permanent diabetes insipidus (DI) (polyuria >250 mL/hr, dilute urine with specific gravity <1.005, hypernatremia) or SIADH.
    • Nasal and Oral Precautions: Avoid nasogastric tubes, nasal suctioning, and toothbrushing for 10–14 days to protect the surgical site; provide gentle mouth rinses and lip moisture instead.
    • Hormone Replacement: Administer prescribed peri-operative glucocorticoids (e.g., hydrocortisone) to prevent adrenal crisis, and educate patients on lifelong hormone replacement if hypopituitarism develops.

Pharmacological Management

Medications are indicated when surgery is contraindicated, when residual tumor remains after surgery, or as bridge therapy while awaiting the effects of radiation.

  • Somatostatin Analogues (Receptor Ligands): Drugs such as octreotide, lanreotide, and pasireotide mimic natural somatostatin to inhibit GH secretion and reduce tumor volume. Monitor patients for abdominal cramps, diarrhea, steatorrhea, cholelithiasis (gallstones), and hyperglycemia (especially with pasireotide).
  • GH Receptor Antagonist: Pegvisomant blocks GH receptors on target tissues, effectively lowering IGF-1 levels and improving symptoms even when somatostatin analogues fail. Because it does not shrink the tumor and carries a risk of hepatotoxicity, nurses must monitor baseline and serial liver function tests (LFTs) and MRI follow-ups.
  • Dopamine Agonists: Oral agents such as cabergoline and bromocriptine suppress GH in selected patients with mild disease or mixed GH/prolactin-secreting adenomas. Monitor for orthostatic hypotension, nausea, and dizziness.

Radiation Therapy

Stereotactic radiosurgery (e.g., Gamma Knife) or conventional fractionated radiotherapy is used as an adjunct when surgery and medical therapy fail to control tumor growth or hormone levels. Because radiation lowers GH levels gradually over years, medical therapy is continued in the interim, and patients require lifelong monitoring for delayed hypopituitarism.

Advertisements

Complications

Untreated or poorly controlled acromegaly and gigantism increase morbidity and mortality primarily due to cardiovascular, respiratory, and metabolic complications:

  • Cardiovascular Disease: Systemic hypertension, left ventricular hypertrophy, biventricular cardiomyopathy, arrhythmias, valvular disease, and congestive heart failure.
  • Endocrine and Metabolic Disorders: Insulin resistance and secondary diabetes mellitus; hypopituitarism (hypothyroidism, adrenal insufficiency, hypogonadism); delayed sexual development in childhood-onset gigantism; menstrual irregularities/infertility in females; and erectile dysfunction (impotence) in males.
  • Respiratory Complications: Obstructive sleep apnea leading to chronic daytime fatigue, impaired concentration, and pulmonary hypertension.
  • Neurological and Visual Loss: Progressive optic nerve atrophy and permanent visual field loss; debilitating carpal tunnel syndrome and degenerative arthropathy/kyphosis.
  • Gastrointestinal and Neoplastic Risks: Visceromegaly (heart, liver, spleen), colonic polyps with increased risk of colorectal cancer, and gallstones (cholelithiasis) (especially during somatostatin analogue therapy).

Nursing Management and Care Plan

Key Nursing Interventions

  1. Comprehensive Baseline Assessment: Monitor vital signs, cardiovascular status (blood pressure, heart rate, peripheral edema), neurological status, visual fields, and musculoskeletal mobility regularly.
  2. Pain and Comfort Management: Assess joint pain, carpal tunnel discomfort, and headaches using a standardized pain scale; administer prescribed analgesics and support joint protection (e.g., splints, supportive footwear, gentle range-of-motion exercises).
  3. Metabolic and Endocrine Surveillance: Monitor blood glucose levels, HbA1c, and serial IGF-1/GH laboratory trends; administer prescribed somatostatin analogues, pegvisomant, or dopamine agonists and monitor for drug-specific adverse effects (LFTs, biliary symptoms, orthostasis).
  4. Airway and Sleep Safety: Screen for loud snoring and apneic episodes; encourage lateral sleeping or head-of-bed elevation, and reinforce adherence to continuous positive airway pressure (CPAP) therapy if prescribed.
  5. Psychosocial and Body Image Support: Use therapeutic communication to validate feelings regarding irreversible facial and acral changes; encourage self-care and participation in peer support groups or counseling.
  6. Safety and Fall Prevention: Adapt the environment for patients with bitemporal hemianopsia (keep pathways clear, place items within central visual field, assist with ambulation as needed).
  7. Health Education and Long-Term Follow-Up: Educate the patient and family on disease pathophysiology, medication adherence, balanced nutrition for glycemic and bone health, warning signs of visual deterioration or adrenal crisis, and the necessity of lifelong endocrine and MRI follow-up.

Advertisements

Nursing Process Framework (NANDA-I 2024–2026)

In line with the Nurses Revision Uganda Nursing Process guidelines and the NANDA International (NANDA-I) 2024–2026 (13th Edition) taxonomy, the care plan below differentiates:

  • Actual (Problem-Focused) Nursing Diagnoses: Written in three-part PES format (NANDA-I 2024–2026 Diagnostic Label + related to etiology/pathophysiology + as evidenced by subjective/objective assessment cues).
  • Potential (Risk) Nursing Diagnoses: Written in two parts (Risk for ... + related to risk factors/pathophysiology), with no “as evidenced by” clause.
  • SMART Planning and Evaluation: Goals are Specific, Measurable, Attainable, Realistic, and Time-oriented (short-term: minutes to 5 days; intermediate: 5–30 days; long-term: 30 days to years). Expected outcomes are written in the future tense, and evaluations are documented in the past tense.

Nursing Care Plan for Acromegaly and Gigantism

AssessmentNursing Diagnosis (NANDA-I 2024–2026)Planning (Goals & Expected Outcomes)Nursing InterventionsRationaleEvaluation

Subjective: Patient states, “People stare at my jaw and big hands, and I hate going out in public.”

Objective: Coarse facial features, prognathism, enlarged hands/feet; avoids looking in mirrors and declines visitors.

Disrupted body image (formerly Disturbed body image) related to chronic skeletal and soft-tissue overgrowth secondary to GH/IGF-1 excess as evidenced by verbalized negative feelings about appearance and social withdrawal.

Short-Term Goal (within 5 days): Patient will verbalize feelings about physical changes and identify two positive personal strengths.

Expected Outcomes:

– Patient will participate in daily grooming and social interaction without avoidance.

– Patient will demonstrate adaptive coping behaviors regarding appearance.

– Establish a trusting, nonjudgmental therapeutic relationship and encourage open expression of grief or embarrassment.

– Clarify realistically which soft-tissue changes may improve after treatment and which bony changes are permanent.

– Encourage participation in personal grooming, well-fitting comfortable clothing/footwear, and support groups or counseling.

– Active listening validates distress and reduces emotional isolation.

– Realistic expectations prevent false hope and support psychological adaptation.

– Grooming and peer support restore self-esteem and reinforce social engagement.

Goal Met: After 5 days, the patient verbalized acceptance of body changes, identified personal strengths, and engaged with family visitors.

Subjective: Patient reports persistent aching in knees, hips, and hands rated 6/10 and recurrent headaches for >3 months.

Objective: Joint swelling, crepitus, limited range of motion, facial grimacing, guarding during ambulation.

Chronic pain related to articular cartilage hypertrophy, osteoarthritis, and dural/nerve compression as evidenced by self-report of pain 6/10 for over 3 months, guarding, and reduced joint mobility.

Short-Term Goal (within 48 hours): Patient will report reduction of pain from 6/10 to ≤2/10.

Expected Outcomes:

– Patient will demonstrate comfortable movement and perform basic ADLs with minimal guarding.

– Patient will utilize two non-pharmacological pain relief techniques.

– Assess pain location, quality, intensity (0–10 scale), and aggravating factors regularly.

– Administer prescribed analgesics, NSAIDs, or somatostatin analogues on schedule and evaluate response.

– Apply warm compresses to stiff joints, support joints with pillows, and collaborate with physiotherapy for gentle low-impact exercises.

– Ongoing pain assessment guides timely titration of therapy.

– Scheduled analgesia and GH suppression reduce joint inflammation and headache frequency.

– Heat and low-impact mobility preserve joint function without overloading hypertrophied cartilage.

Goal Met: Within 48 hours, the patient reported joint pain reduced to 2/10 and performed morning ADLs without grimacing.

Subjective: Patient reports waking up gasping for air, unrefreshing sleep, and severe daytime drowsiness.

Objective: Loud snoring, witnessed nocturnal apneic episodes, macroglossia, thickened pharyngeal tissues, dark under-eye circles.

Ineffective sleep pattern (formerly Disturbed sleep pattern) related to upper airway narrowing from macroglossia and pharyngeal soft-tissue hypertrophy as evidenced by loud snoring, witnessed apneas, and daytime somnolence.

Intermediate Goal (within 7 days): Patient will achieve 6–8 hours of uninterrupted sleep per night.

Expected Outcomes:

– Patient will verbalize feeling rested on waking.

– Patient will demonstrate correct use of airway-supportive sleeping positions or prescribed CPAP.

– Elevate the head of the bed 30° or encourage side-lying rather than supine positioning.

– Monitor respiratory rate, oxygen saturation, and apneic episodes during sleep.

– Coordinate sleep study evaluation and reinforce adherence to prescribed CPAP therapy; avoid unnecessary sedatives.

– Head elevation and lateral positioning prevent posterior displacement of the enlarged tongue into the airway.

– Nocturnal monitoring detects hypoxemia early.

– CPAP maintains airway patency, while sedatives depress respiratory drive and worsen airway collapse.

Goal Met: After 7 days, the patient slept 7 hours with fewer nighttime awakenings and reported improved daytime alertness.

Subjective: Patient states, “I am terrified I will go blind or die during pituitary surgery.”

Objective: Restlessness, tense posture, frequent questioning, heart rate 104 bpm, BP 148/90 mmHg.

Excessive anxiety (formerly Anxiety) related to threat of visual loss, chronic illness uncertainty, and impending surgery as evidenced by verbalized fear, restlessness, and tachycardia (104 bpm).

Short-Term Goal (within 24 hours): Patient will verbalize reduced anxiety and vital signs will stabilize (HR 60–100 bpm).

Expected Outcomes:

– Patient will demonstrate relaxation techniques during stressful periods.

– Patient will express realistic understanding of planned surgical/medical procedures.

– Assess level of anxiety and provide a calm, unhurried environment.

– Provide clear, simple explanations of diagnostic tests, visual monitoring, and transsphenoidal surgery steps.

– Teach guided deep-breathing and progressive muscle relaxation exercises.

– Identifying anxiety severity allows tailored psychological intervention.

– Accurate procedural information reduces fear of the unknown.

– Relaxation techniques activate the parasympathetic nervous system, lowering heart rate and tension.

Goal Met: Within 24 hours, the patient reported reduced anxiety, practiced deep breathing independently, and heart rate decreased to 82 bpm.

Subjective: Patient expresses helplessness (“Nothing I do will ever fix my body”) and avoids discussing follow-up care.

Objective: Irritability, withdrawn affect, missed outpatient appointments prior to admission.

Maladaptive coping (formerly Ineffective coping) related to chronic progressive physical changes and inadequate stress-management support as evidenced by expressed helplessness, irritability, and avoidance of treatment planning.

Intermediate Goal (within 14 days): Patient will demonstrate effective problem-focused and emotion-focused coping strategies.

Expected Outcomes:

– Patient will actively participate in treatment decision-making.

– Patient will identify available family or community support resources.

– Assess current coping strategies, cultural beliefs, and available social support systems.

– Involve family members (with consent) in care discussions and refer to a medical social worker or psychologist.

– Break long-term management into manageable short-term steps and reinforce positive health actions.

– Evaluating baseline coping reveals gaps in problem-solving and support.

– Family and professional counseling strengthen resilience and reduce feelings of helplessness.

– Achievable short-term milestones restore a sense of control.

Goal Met: Within 14 days, the patient attended counseling, involved family in care planning, and scheduled follow-up reviews.

Subjective: Patient asks, “Why do I need lifelong blood tests after surgery, and why can’t I blow my nose?”

Objective: Unable to state post-operative CSF leak precautions or purpose/side effects of octreotide and pegvisomant.

Inadequate health knowledge (formerly Deficient knowledge) related to limited prior exposure to complex endocrine and surgical care as evidenced by inaccurate statements and repeated questions regarding treatment.

Short-Term Goal (before discharge / within 3 days): Patient will accurately explain disease process, medication regimen, and red-flag symptoms.

Expected Outcomes:

– Patient will correctly demonstrate teach-back of post-operative nasal precautions.

– Patient will state schedule for IGF-1, LFT, and MRI follow-up.

– Assess baseline health literacy and preferred learning style in a quiet setting.

– Teach using plain language and the teach-back method covering medications, CSF leak signs, adrenal crisis symptoms, and lifelong follow-up.

– Provide written discharge instructions and emergency contact numbers.

– Tailoring education to literacy level improves comprehension.

– Teach-back verifies actual patient understanding rather than passive listening.

– Written resources support safe self-management after discharge.

Goal Met: Prior to discharge, the patient accurately explained post-op nasal precautions, medication side effects, and follow-up dates using teach-back.

Subjective: Patient reports occasional mild exertional dyspnea and palpitations.

Objective: BP 156/94 mmHg; ECG and echocardiogram reveal left ventricular hypertrophy (cardiomegaly).

Risk for impaired cardiovascular function related to GH/IGF-1-induced myocardial hypertrophy, sodium retention, and systemic hypertension.

Intermediate Goal (within 14 days): Patient will maintain stable hemodynamic status with BP <130/80 mmHg.

Expected Outcomes:

– Patient will remain free from chest pain, worsening dyspnea, or peripheral edema.

– Patient will adhere to prescribed antihypertensive therapy and low-sodium diet.

– Monitor blood pressure, heart rate/rhythm, lung sounds, and peripheral edema every shift.

– Administer prescribed antihypertensives and GH-lowering therapy; monitor ECG and echocardiogram results.

– Educate patient on sodium restriction, gradual activity pacing, and reporting dyspnea or orthopnea immediately.

– Serial cardiovascular assessment detects early heart failure or arrhythmias.

– Controlling blood pressure and GH/IGF-1 reduces ventricular workload and slows cardiac remodeling.

– Sodium restriction reduces fluid retention and preload.

Goal Met: At 14-day review, the patient maintained BP at 126/78 mmHg with clear lung fields and no peripheral edema.

Subjective: Patient reports increased thirst and frequent urination; unfamiliar with blood glucose targets.

Objective: Fasting blood glucose 7.8 mmol/L; lacks home glucose monitoring routine.

Risk for ineffective blood glucose pattern self-management related to GH-induced insulin resistance and insufficient knowledge of glycemic monitoring.

Short-Term Goal (within 5 days): Patient will maintain blood glucose within target range (4.0–7.0 mmol/L fasting) and demonstrate safe monitoring.

Expected Outcomes:

– Patient will demonstrate accurate capillary blood glucose testing.

– Patient will identify signs of hyperglycemia and hypoglycemia.

– Monitor capillary blood glucose as ordered (especially if on pasireotide or corticosteroids) and review HbA1c.

– Administer prescribed antidiabetic agents or insulin and coordinate dietitian referral for balanced meal planning.

– Teach fingerstick monitoring, symptom recognition, and regular safe exercise.

– Frequent monitoring identifies GH- or drug-induced hyperglycemia promptly.

– Diet and pharmacotherapy stabilize blood glucose and prevent microvascular complications.

– Self-monitoring skills empower safe long-term glycemic control.

Goal Met: Within 5 days, fasting blood glucose stabilized at 5.9 mmol/L and the patient independently demonstrated glucometer use.

Subjective: Patient reports profuse sweating (hyperhidrosis) and is scheduled for transsphenoidal pituitary surgery.

Objective: Moist skin, potential for post-operative polyuria from transient diabetes insipidus or osmotic diuresis.

Risk for inadequate fluid volume (replaces Fluid volume deficit) related to excessive diaphoresis, hyperglycemia-induced osmotic diuresis, and potential post-operative diabetes insipidus.

Short-Term Goal (throughout peri-operative stay): Patient will maintain balanced fluid status (urine output 0.5–1 mL/kg/hr; normal skin turgor and serum sodium 135–145 mmol/L).

Expected Outcomes:

– Patient will maintain moist mucous membranes and stable vital signs without orthostatic hypotension.

– Urine specific gravity will remain within normal limits (1.005–1.030).

– Record strict intake and output, daily body weights, and urine specific gravity (hourly post-transsphenoidal surgery).

– Monitor serum electrolytes (especially sodium) and assess mucous membranes and skin turgor.

– Encourage oral fluids as tolerated, administer prescribed IV fluids or desmopressin (DDAVP) if DI occurs, and report polyuria (>250 mL/hr) immediately.

– Strict I&O and specific gravity rapidly detect post-operative diabetes insipidus before severe dehydration develops.

– Electrolyte tracking prevents hypernatremia and hypovolemic shock.

– Timely fluid replacement and desmopressin restore water balance.

Goal Met: Throughout admission, the patient maintained urine output of 50–80 mL/hr, urine specific gravity 1.015, and serum sodium 140 mmol/L.

Subjective: Patient reports numbness and tingling in the thumb, index, and middle fingers, plus bumping into doorways on the sides.

Objective: Decreased grip strength, positive Phalen sign, bitemporal hemianopsia on confrontation visual field testing.

Risk for impaired peripheral neurovascular function related to soft-tissue compression of median nerves (carpal tunnel syndrome) and skeletal hypertrophy; Risk for adult falls related to bitemporal visual field loss and joint instability.

Long-Term Goal (within 30 days): Patient will remain free from falls, thermal/pressure injuries, and progressive sensory loss.

Expected Outcomes:

– Patient will utilize wrist splints and visual scanning techniques safely during ambulation.

– Patient will report stabilized or reduced hand paresthesia.

– Perform regular neurovascular checks (capillary refill, sensation, grip strength) and visual field assessments.

– Apply neutral wrist splints as ordered, keep bed low with call bell in reach, remove clutter, and teach head-turning visual scanning.

– Educate patient to test water temperature before bathing and inspect extremities daily for unnoticed injuries.

– Routine checks detect worsening nerve or optic chiasm compression early.

– Neutral splints reduce median nerve pressure, while environmental modifications and visual scanning compensate for peripheral vision loss to prevent falls.

– Temperature precautions prevent burns when sensory perception is diminished.

Goal Met: At 30-day follow-up, the patient experienced zero falls or injuries, used visual scanning consistently, and reported reduced hand tingling.

Quick Quiz

Acromegaly & Gingatism Quiz

Medical Nursing

Privacy: Your details are used only for quiz tracking and certificates.

Advertisements

4 thoughts on “Acromegaly & Gingatism (Hyperpituitarism)”

  1. thanks for the information, but I wish you start the idea of managing these conditions using a nursing process, but all fails please always make some nursing diagnoses, thanks so much

Leave a Comment

Your email address will not be published. Required fields are marked *

Want notes in PDF? Join our classes!!

Send us a message on WhatsApp
0726113908

Scroll to Top
Enable Notifications OK No thanks